Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.350
+0.020 (0.86%)
At close: Sep 25, 2026, 4:00 PM EDT
2.330
-0.020 (-0.85%)
Pre-market: Sep 28, 2026, 5:08 AM EDT
Fate Therapeutics Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Fate Therapeutics stock has a consensus rating of "Buy" and an average price target of $5.74. The average 1-year stock price forecast is 144.26% higher than the current stock price, while the lowest is $2.20 (-6.38%) and the highest is $8.00 (+240.43%).
Price Target: $5.74 (+144.26%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Aug 17, 2026.
Analyst Ratings
The average analyst rating for Fate Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 12 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Mizuho Securities No rating | Mizuho Securities | Buy Maintains $8 | Buy | Maintains | $8 | +240.43% | Aug 17, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Buy Maintains $7 | Buy | Maintains | $7 | +197.87% | Aug 14, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $6 → $8 | Buy | Reiterates | $6 → $8 | +240.43% | Aug 14, 2026 |
Unknown Analyst Wells Fargo No rating | Wells Fargo | Hold Reiterates $2.5 → $3.5 | Hold | Reiterates | $2.5 → $3.5 | +48.94% | Aug 14, 2026 |
| Needham | Needham | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Aug 13, 2026 |
Financial Forecast
Revenue This Year
5.65M
from 6.65M
Decreased by -15.00%
Revenue Next Year
4.77M
from 5.65M
Decreased by -15.63%
EPS This Year
-1.02
from -1.15
EPS Next Year
-0.97
from -1.02
EPS and Forward PE are based on non-GAAP adjusted numbers.